Skip to main content
David Callanan, MD, Ophthalmology, Arlington, TX

DavidCallananMD

Ophthalmology Arlington, TX

Retinal Disease

Physician

Dr. Callanan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Callanan's full profile

Already have an account?

  • Office

    801 W Randol Mill Rd
    Suite 101
    Arlington, TX 76012
    Phone+1 817-261-9625

Education & Training

  • University of Miami/Jackson Health System/Bascom Palmer Eye Institute
    University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 1990 - 1992
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Ophthalmology, 1987 - 1990
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1983 - 1985
  • University of Iowa Roy J. and Lucille A. Carver College of Medicine
    University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1983
  • Luther College
    Luther CollegeB.A., 1975

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1984 - 2026
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
  • Senior Honor Award American Society of Retinal Specialists, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel  
    Regillo CD, Callanan DG, Fine HF, Do DV, Holekamp NM, Kuppermann BD, Singer MA, Singh RP, Ophthalmic Surg Lasers Imaging Retina, 1/1/2017
  • A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema  
    Callanan DG, Loewenstein A, Patel SS, Massin P, Corcostegui B, Li XY, Jiao J, Hashad Y, Whitcup SM, Graefes Arch Clin Exp Ophthalmol, 1/1/2017
  • Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study  
    Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, Do D, Ophthalmology, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • "Combination Therapy for Exudative Age Related Macular Degeneration"
    Callanan DG, XXVIth Meeting of the Club Jules Gonin, St. Moritz, Switzerland, 1/12/2008
  • Fluocinolone Acetonide Intravitreal Implant for the Treatment of Uveitis Affecting the Posterior Segment: 34 Week Results of a Randomized, Masked, Multi-center Clinica...
    Fluocinolone Acetonide Uveitis Study Group, American Uveitis Society, Vail, CO, 1/19/2004

Lectures

  • "The OZAB Study: A 6 Month, Prospective, Randomized Study of the Effects of Dexamethasone Intravitreal Implant with Bevacizumab Compared to Bevacizumab Alone for Centr... 
    Jersey, The Channel Islands - 1/13/2018
  • "Implantation of Drug Delivery Devices" 
    Guangzhou, China - 1/13/2017
  • "Abicipar Pegol (Anti-Vegf Darpin) Phase 2, Doublemasked, Randomized Study In Treatment-Na�ve Patients With Neovascular Age-Related Macular Degeneration" 
    Bordeaux, France - 1/7/2016
  • Join now to see all

Other

  • Guidelines for Interpreting Retinal Photographs and Coding Findings in the Submacular Surgery trials: SSt report NO. 8. 
    Submacular Surgery Trials Research Group
  • Histo-pathological and Ultrastructural Features of Surgically-excised Subfoveal Choroidal Neovascular Lesions: SST Report NO. 7. 
    Submacular Surgery Trials Research Group

Press Mentions

  • Aviceda Completes Enrollment for Phase 2b SIGLEC Study for Geographic Atrophy Treatment
    Aviceda Completes Enrollment for Phase 2b SIGLEC Study for Geographic Atrophy TreatmentSeptember 24th, 2024
  • Aviceda Therapeutics Announces Formation of Executive Team
    Aviceda Therapeutics Announces Formation of Executive TeamJanuary 11th, 2021
  • NEW PRODUCT APPLICATIONS: Yutiq Implant for Chronic Noninfectious Posterior-Segment Uveitis
    NEW PRODUCT APPLICATIONS: Yutiq Implant for Chronic Noninfectious Posterior-Segment UveitisApril 1st, 2019

Professional Memberships